Cited by 18PI3K/AKT/mTOR signaling in cancerPancreatic function and diabetesNeuroendocrine Tumor Research Advances

Activated mTOR/P70S6K Signaling Pathway Is Involved in Insulinoma Tumorigenesis

Zhan, Han‐Xiang, Cong, Lin, Zhao, Yu‐Pei, Zhang, Tai‐Ping, Chen, Ge, Zhou, Li, Guo, Jun‐Chao·2012·Journal of Surgical Oncology

Abstract

Background Insulinoma was a rare tumor and its pathogenesis was poorly understood. There had no study that focused on the role of mTOR signaling pathway in insulinoma tumorigenesis. Materials and methods Expression of p-mTOR and its downstream p-P70S6K in insulinoma and normal pancreatic tissue was evaluated by immunohistochemical staining and Western blotting. In vitro study, an insulinoma cell line (INS-1) was treated with inhibitors of mTOR (rapamycin) or dual PI3K/mTOR inhibitor (NVP-BEZ235), RT-PCR, and Western blotting were applied to evaluate their influence on the expression of mTOR and P70S6K. Cell proliferation was evaluated by MTT test, cell cycle and apoptosis were analyzed by flow cytometry, insulin secretion level was evaluated by GSIS method. Results Positive expression of p-mTOR and p-P70S6K was much higher in insulinoma tumor specimens than the normal pancreatic islet (P Conclusion mTOR/P70S6K signaling pathway is involved in tumorigenesis of insulinoma, NVP-BEZ235 and rapamycin offer a promising role as novel drugs in treatment of insulinoma.

Integrity signals

Registry

Crossref · 10.1002/jso.23176

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increased expression and activation of the mTOR pathway was discovered in insulinoma tumors and appears to be involved in upregulating tumor growth and insulin secretion.

    “Increased expression and activation of this pathway was discovered in insulinoma tumors and appears to be involved in upregulating tumor growth and insulin secretion [85].”

Cited by

Sorted by citations

Authors
Zhan, H., Cong, L., Zhao, Y., Zhang, T., Chen, G., Zhou, L., & Guo, J.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Zhao, Yu‐Pei
Venue
Journal of Surgical Oncology
Publisher
Wiley
Published
2012-06-18
Volume
106
Issue
8
Pages
972-980
ISSN
  • 0022-4790 (ISSN-L)
  • 1096-9098
OpenAlex
W2136333609
Cited by
18
References
0
Citations by year
2025: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 3 · 2015: 1 · 2012: 1
FWCI
0.26
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Surgical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Peking Union Medical College Hospital
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
Keywords
insulinoma, mTOR signaling, p70S6K, carcinogenesis, rapamycin, NVP-BEZ235, PI3K/mTOR inhibitors, INS-1 cells, cell proliferation, apoptosis, insulin secretion, pancreatic islets, mTOR inhibitors
MeSH terms
Adult, Female, Humans, Insulinoma, Male, Middle Aged, Signal Transduction, Ribosomal Protein S6 Kinases, 70-kDa, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review